Department of Oral and Maxillofacial Surgery, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, the Netherlands; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Eur J Surg Oncol. 2021 Aug;47(8):1934-1939. doi: 10.1016/j.ejso.2021.03.242. Epub 2021 Apr 20.
The aim of this study was to determine the incidence, location and timing of second primary tumours (SPT) after diagnosis of oral squamous cell carcinoma (OSCC) and relate the risk of SPT to that after head and neck squamous cell carcinoma (HNSCC) and the risks of those tumours in the general population in order to assess the need for a separate follow-up programme for OSCC patients and to aid development of an evidence-based and individualized follow-up programme for OSCC patients.
All patients diagnosed with OSCC or HNSCC in the Netherlands in 1991-2015 were selected from the Netherlands Cancer Registry. Cumulative incidence rates and Standardized Incidence Ratios (SIR) were calculated. Analyses were stratified by incidence period and age at primary diagnosis of the index tumour, follow-up time, and site of the SPT.
We included 11263 patients with OSCC from a population of 34244 patients with HNSCC, of which the median follow-up time was 4.0 years. OSCC SPT develop in different patterns and at different locations than after HNSCC. The 5-year risk of SPT and SIR (95% confidence intervals) were respectively 0.13 (0.13-0.14) and 3.0 (2.9-3.1) for OSCC. The risk of a SPT was continuous over follow-up time and calendar period but decreased with an increasing age at diagnosis of the index tumour up to the age of 75 and there were differences in sites of SPT.
A specific follow-up protocol for OSCC is needed, which can be individualized on the basis of, among others, age.
本研究旨在确定口腔鳞状细胞癌(OSCC)诊断后第二原发肿瘤(SPT)的发病率、部位和时间,并将 SPT 风险与头颈部鳞状细胞癌(HNSCC)和普通人群中这些肿瘤的风险进行比较,以评估是否需要为 OSCC 患者制定单独的随访方案,并为 OSCC 患者制定循证和个体化的随访方案提供依据。
从荷兰癌症登记处选取 1991 年至 2015 年期间诊断为 OSCC 或 HNSCC 的所有患者。计算累积发病率和标准化发病率比(SIR)。分析按发病期、指数肿瘤的原发诊断年龄、随访时间和 SPT 部位进行分层。
我们纳入了 11263 例 OSCC 患者,这些患者来自 34244 例 HNSCC 患者,中位随访时间为 4.0 年。OSCC SPT 的发病模式和部位与 HNSCC 不同。5 年 SPT 风险和 SIR(95%置信区间)分别为 0.13(0.13-0.14)和 3.0(2.9-3.1)。SPT 风险随随访时间和日历时间的延长而持续增加,但随指数肿瘤诊断年龄的增加(直至 75 岁)而降低,且 SPT 部位存在差异。
需要为 OSCC 制定专门的随访方案,该方案可根据年龄等因素进行个体化制定。